Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Aug 15, 2019; 11(8): 634-641
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Table 2 Neoadjuvant chemotherapy adverse events
| Maximal toxicity | All | Grade 3/4 |
| All | 31 (92) | 10 (30) |
| Neutropenia | 3 (10) | 1(3) |
| Febrile neutropenia | 1 (3) | 1 (3) |
| Anaemia | 2 (6) | 0% |
| Thrombocytopenia | 2 (6) | 0% |
| Neurotoxicity | 21 (63) | 7 (21) |
| Nausea | 7 (21) | 0% |
| Asthenia | 12 (36) | 6 (19) |
| Vomiting | 2 (6) | 0% |
| Mucositis | 4 (12) | 2 (6) |
| Diarrhoea | 12 (36) | 3 (10) |
| Allergic reaction | 1(3) | 1 (3) |
- Citation: Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F. Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. World J Gastrointest Oncol 2019; 11(8): 634-641
- URL: https://www.wjgnet.com/1948-5204/full/v11/i8/634.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i8.634